-
Dominant Head moves into Bradman territory with fourth Adelaide ton
-
Arsenal battle to stay top of Christmas charts
-
Mexican low-cost airlines Volaris and Viva agree to merger
-
Border casinos caught in Thailand-Cambodia crossfire
-
Australia's Head slams unbeaten 142 to crush England's Ashes hopes
-
Epstein files due as US confronts long-delayed reckoning
-
'Not our enemy': Rush to rearm sparks backlash in east Germany
-
West Indies 110-0, trail by 465, after Conway's epic 227 for New Zealand
-
Arsonists target Bangladesh newspapers after student leader's death
-
Volatile Oracle shares a proxy for Wall Street's AI jitters
-
Tears at tribute to firefighter killed in Hong Kong blaze
-
Seahawks edge Rams in overtime thriller to seize NFC lead
-
Teenager Flagg leads Mavericks to upset of Pistons
-
Australia's Head fires quickfire 68 as England's Ashes hopes fade
-
Japan hikes interest rates to 30-year-high
-
Brazil's top court strikes down law blocking Indigenous land claims
-
Conway falls for 227 as New Zealand pass 500 in West Indies Test
-
'We are ghosts': Britain's migrant night workers
-
Asian markets rise as US inflation eases, Micron soothes tech fears
-
Giant lanterns light up Christmas in Catholic Philippines
-
TikTok: key things to know
-
Putin, emboldened by Ukraine gains, to hold annual presser
-
Deportation fears spur US migrants to entrust guardianship of their children
-
Upstart gangsters shake Japan's yakuza
-
Trump signs $900 bn defense policy bill into law
-
Stokes's 83 gives England hope as Australia lead by 102 in 3rd Test
-
Go long: the rise and rise of the NFL field goal
-
Australia announces gun buyback, day of 'reflection' after Bondi shooting
-
New Zealand Cricket chief quits after split over new T20 league
-
England all out for 286, trail Australia by 85 in 3rd Test
-
Australian announces gun buyback, day of 'reflection' after Bondi shooting
-
Joshua takes huge weight advantage into Paul fight
-
TikTok signs joint venture deal to end US ban threat
-
Conway's glorious 200 powers New Zealand to 424-3 against West Indies
-
The European "Anti-Trend" Has Arrived
-
LEXINOVA Trading Center Releases New Brand Positioning Strategy Focused on Global Compliance and Institutional-Grade Infrastructure
-
Guardian Metal Resources PLC Announces Pilot Mountain Pre-Feasibility Progress Update
-
WNBA lockout looms closer after player vote authorizes strike
-
Honduras begins partial vote recount in Trump-dominated election
-
Nike shares slump as China struggles continue
-
Hundreds swim, float at Bondi Beach to honour shooting victims
-
Crunch time for EU leaders on tapping Russian assets for Ukraine
-
Pope replaces New York's pro-Trump Cardinal with pro-migrant Chicagoan
-
Trump orders marijuana reclassified as less dangerous drug
-
Rams ace Nacua apologizes over 'antisemitic' gesture furor
-
McIlroy wins BBC sports personality award for 2025 heroics
-
Napoli beat Milan in Italian Super Cup semi-final
-
Violence erupts in Bangladesh after wounded youth leader dies
-
EU-Mercosur deal delayed as farmers stage Brussels show of force
-
US hosting new Gaza talks to push next phase of deal
Lumira Ventures Announces Promotion of Suman Rao to Principal
Lumira Ventures, a leading North American life sciences investment firm dedicated to advancing healthcare innovation and enhancing patient outcomes, is pleased to announce the promotion of Suman Rao, Ph.D., to the role of Principal. This well-deserved promotion acknowledges her significant contributions to the firm's success and her steadfast commitment to fostering innovative healthcare solutions.
Dr. Rao joined Lumira Ventures in 2021 as an Associate and was promoted to Senior Associate in 2024, as she built out her skills and experience in all dimensions of the venture capital value chain. Her deep understanding of industry sectors like oncology and neuroscience coupled with her ability to foster strong relationships with entrepreneurs, co-investors, and industry stakeholders has made her a sought-after team member. Dr. Rao has been deeply involved with the firm's investments in Arclight Therapeutics, Congruence Therapeutics, and Damona Pharmaceuticals (as a board observer). Her contributions extend to being actively engaged in a number of the firm's strategic initiatives, including the Angelini Lumira Biosciences Fund and currently co-leading the Cancer Breakthrough Fund, a first-of-its-kind collaboration in Canada between a philanthropic organization (Terry Fox Foundation) and a VC firm with the goal to bring more capital to the mission of finding cures for cancers.
"We are delighted to elevate Suman to the role of Principal," said Peter van der Velden, Managing General Partner at Lumira Ventures. "Her growth at the firm and ability to take on more responsibility reflects our commitment to growing talent in-house and her dedication to developing the skills, expertise, and relationships that are the foundation of being a great VC."
"I am thrilled to be stepping into the role of Principal and grateful for the trust and support of my partners and colleagues," said Dr. Rao. "Together with an incredibly talented team, I look forward to supporting passionate entrepreneurs tackling some of medicine's biggest challenges today and building transformative companies."
Dr. Rao earned her Ph.D. in Experimental Medicine and her Bachelor's degree in Biochemistry from McGill University. Before joining Lumira Ventures, she completed a prestigious postdoctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Rao also brings valuable experience from her time as a management consultant at L.E.K Consulting, where she provided strategic advice to biotech and pharma clients, further honing her expertise in the life sciences sector.
About Lumira Ventures
Lumira Ventures is a leading multi-stage life sciences investment firm operating across Toronto, Montréal, Vancouver, and Boston. As Canada's largest and most active dedicated life sciences venture capital investor, Lumira invests in first-in-class innovations in "secondary" geographies, partnering with mission-driven entrepreneurs to develop transformative therapeutics products and medical devices while generating strong financial returns and societal impact.
With a proven track record, Lumira Ventures has consistently delivered both financial success and transformative medical advancements. With portfolio companies having introduced over 50 biomedical innovations, improving the lives of over 1 billion patients worldwide and generating more than $70B in cumulative revenue.
For more information, please contact: [email protected]
www.lumiraventures.com
SOURCE: Lumira Ventures
L.Mason--AMWN